Selective Targeting of Cancer Cells by Oxidative Vulnerabilities with Novel Curcumin Analogs

Area of Science:

• Biochemistry
• Pharmacology
• Oncology

Background:

• Targeting cancer cell oxidative and metabolic vulnerabilities is a key research area.
• Natural compounds like curcumin show promise but face limitations in stability and bioavailability.
• High doses of curcumin are often required, limiting clinical efficacy.

Purpose of the Study:

• To synthesize and evaluate novel monocarbonyl analogs of curcumin for enhanced anti-cancer activity.
• To investigate the mechanism of action, including reactive oxygen species generation and apoptosis induction.
• To assess the in vivo efficacy and safety of promising curcumin analogs.

Main Methods:

• Synthesis of monocarbonyl analogs of curcumin.
• In vitro evaluation of anti-cancer activity in various human cancer cell lines.
• Assessment of reactive oxygen species generation and mitochondrial apoptosis pathway.
• In vivo studies using mouse xenograft models of triple-negative breast cancer and leukemia.

Main Results:

• Two novel analogs (Compound A and I) exhibited increased chemical stability and superior anti-cancer activity compared to curcumin.
• These analogs selectively induced reactive oxygen species in cancer cells, leading to mitochondrial dysfunction and apoptosis.
• Compound A, in combination with piperlongumine, showed an additive anti-cancer effect.
• Compound A demonstrated good tolerability in mice and inhibited tumor growth in vivo.

Conclusions:

• Monocarbonyl curcumin analogs possess enhanced stability and potent anti-cancer properties.
• Selective induction of oxidative stress is a viable strategy for cancer eradication.
• Compound A represents a promising therapeutic candidate for aggressive cancers with high potential.